BridgeBio Pharma (BBIO) Other Non-Current Assets (2018 - 2026)

BridgeBio Pharma has disclosed Other Non-Current Assets across 9 years of filings, most recently posting $18.6 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $18.6 million, up 12.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.6 million (up 12.11% YoY), and the FY2025 annual result was $16.7 million, down 8.15% from the prior year.
• Other Non-Current Assets came in at $18.6 million for Q1 2026 at BridgeBio Pharma, up from $16.7 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $35.3 million in Q1 2022 to a low of $16.6 million in Q1 2025.
• The 5-year median for Other Non-Current Assets is $20.3 million (2024), against an average of $21.9 million.
• Across the five-year window, Other Non-Current Assets slumped 41.21% in 2023 and rose 25.78% in 2025, its largest moves.
• BridgeBio Pharma's Other Non-Current Assets stood at $20.2 million in 2022, then rose by 11.87% to $22.6 million in 2023, then dropped by 19.58% to $18.2 million in 2024, then fell by 8.15% to $16.7 million in 2025, then grew by 11.42% to $18.6 million in 2026.
• The last three Other Non-Current Assets figures came in at $18.6 million (Q1 2026), $16.7 million (Q4 2025), and $25.5 million (Q3 2025), per Business Quant data.